The case for & against
Bull & Bear analysis
Arrowhead Pharmaceuticals (NASDAQ: ARWR) is a leading biopharmaceutical company specializing in the development of transformative therapies using its proprietary RNA interference (RNAi) technology. The company's pipeline targets significant unmet medical needs, particularly in cardiometabolic and central nervous system (CNS) diseases, with a pivotal focus on effectively managing severe conditions like familial chylomicronemia syndrome (FCS). The recent approval of its first commercial product, Redempla, positions Arrowhead favorably within the niche of innovative therapeutics aimed at rare diseases.
Bull says
- ↑Redempla FDA-approved for FCS generates 400+ prescriptions post-launch
- ↑FY25 revenue surged to $829 M, cash balance $919 M supports R&D
- ↑Phase 3 data show 80% triglyceride reduction and fewer pancreatitis cases
- ↑Pipeline advancing cardiometabolic and CNS candidates, data expected year-end
- ↑Partnerships with Sarepta and Sanofi provide licensing income and milestone payments
- ↑Strong stock momentum and high institutional ownership underpin positive sentiment
Bear says
- ↓Q2 operating expenses climbed to $731 M, accelerating cash burn
- ↓Q2 net loss of $132.7 M ($0.93/share) clouds near-term profits
- ↓Plazaciran faces PDUFA risk in Nov 2025, potential regulatory delay
- ↓Competition from Ionis and others may erode Arrowhead’s market share
- ↓Negative earnings yield and weak profitability factors heighten risk
- ↓Analyst revisions trending down signal lower growth expectations
Investment themes with ARWR
Genetic and drug innovations driving medical breakthroughs
Earnings Call · Q2 2026 · Mgmt. Guidance
Transcript signals
Bull points
- Revenue for this quarter totaled $74 million, driven primarily by our license and collaboration agreements with Sarepta and with Novartis. On this amount, approximately $42 million related to the Sarepta collaboration. This includes $28 million from ongoing recognition of the initial Sarepta consideration, $10 million related to reimbursement of incurred preclinical collaboration program costs, and $4 million for clinical supply provided to them under a clinical supply agreement.
- In addition, we recognize $20 million of the $200 million upfront payment received from Novartis in October, bringing year-to-date recognition of Novartis upfront to $54 million, with the remaining $146 million to be deferred over time as we fulfill our preclinical obligations.
- As previously discussed, we are continuing to build our commercial capabilities to fully support the FCS launch. We continue to leverage and invest in these capabilities to support Redempto and FCS, while also positioning the organization to support a potential future launch.
Bear points
- net loss for the quarter ended March 31, 2026. It was $132.7 million for a loss of 93 cents per share. This compares the net income of $370.4 million, or $2.75 per share, for the quarter ended March 31st, 2025.
- A particularly important development in the payer landscape is the diagnostic pathway flexibility that major payers are recognizing. The coverage policies taking shape across major payers reflect both genetic testing and clinical criteria as valid routes to diagnosis. This is critical for ensuring that all appropriate redentlo patients can access treatment because a meaningful proportion of real-world SDS patients are clinically diagnosed rather than genetically confirmed. And policies that require genetic confirmation as a prerequisite would create an unnecessary and inappropriate barrier.